A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing ticagrelor 90 mg hard capsules (PG402 [Celon Pharma]) vs ticagrelor 90 mg film-coated tablets (Brilique [AstraZeneca AB]) under fasting conditions in healthy volunteers

You likely can't join if

• 1. Subject with known allergy, hypersensitivity, intolerance or contraindication to ticagrelor, or to any excipients of the formulation, 2. Any known significant current or past acute or chronic disease or condition of the: circulatory, respiratory, hematopoietic, endocrine, nervous, musculoskeletal system, alimentary and urinary tract, allergic disease, genetic or psychiatric disorder or acute infection within 2 weeks before screening that could influence the present general health condition, at the Investigator’s discretion, 3. Congenital or acquired bleeding disorders, 4. Active pathological bleeding, 5. Intracranial haemorrhage in medical history, 6. Patients with a propensity to bleed (e.g. due to recent trauma, recent surgery, coagulation disorders, active or recent gastrointestinal bleeding), 7. Bradycardic-related syncope in medical history, 8. Current disease of the alimentary tract, liver or kidneys that may influence absorption, distribution and/or elimination of the studied drug, as assessed by the Investigator and documented in medical history, 9. Medical condition that requires administration of other drugs or use of any drug within the 4 weeks preceding the first IMP administration and during the entire study. Drugs commonly used with fast metabolism may be administered and is up to Investigator discretion (i.e. pain killers), 10. Participation in other clinical trials, where at least one dose of study drug was administered, within 90 days preceding the screening phase, 11. Blood drawn within 30 days prior to inclusion in this study (more or equal to 300 mL), 12. Positive results from pregnancy test in female volunteers on Screening Day or before each treatment period, 13. Lactation in female volunteers, 14. Hypotension or hypertension in medical history, on Screening Day or before each treatment period, if Principal Investigator is to assess it as clinically relevant, 15. Narcotic and alcohol addiction or abuse (more than 14 alcohol units per week: one unit = 150 mL wine, 360 mL beer, 45 mL 40 % spirits) (UK guidelines) within last 1 year before screening, 16. Positive results of HBsAg, anti-HCV or anti-HIV, 17. Positive result of antigen Covid-19 test, 18. Positive drug screen or alcohol breath tests, 19. Subjects who adhere to a special diet (e.g. low calories, vegetarian, etc.), 20. The subject is considered by the Investigator to be an unsuitable candidate to participate in the study for any reason.